Drug intelligence / Profile preview

zidovudine + lamivudine + nevirapine + nelfinavir

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of four antiretroviral drugs used for HIV treatment. It combines two nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine), one non-nucleoside reverse transcriptase inhibitor (nevirapine), and one protease inhibitor (nelfinavir). While the triple combinations of zidovudine + lamivudine + nevirapine and zidovudine + lamivudine + nelfinavir have been studied separately as HIV treatments, the four-drug combination is not documented as a standard regimen in the provided information.

Targets

Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)

Beyond the preview

Go deeper on zidovudine + lamivudine + nevirapine + nelfinavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zidovudine + lamivudine + nevirapine + nelfinavir.

Explore the full profile